DeepMed Research

ALCON RESEARCH

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD)

Phase 3

Completed

Conditions: Macular Degeneration

Interventions: Drug: Anecortave Acetate Sterile Suspension, 30 mg/mL
Drug: Anecortave Acetate Sterile Suspension, 60 mg/mL
Other: Anecortave Acetate Vehicle

First Posted Date: 2006-03-07

Last Posted Date: 2012-11-28

Lead Sponsor: Alcon Research

Target Recruit Count: 240

Registration Number: NCT00299507

Locations: 🇺🇸
Alcon Study Sites, Fort Worth, Texas, United States

A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

Phase 3

Completed

Conditions: Ocular Hypertension
Open-angle Glaucoma

Interventions: Drug: Travoprost (TRAVATAN)
Drug: Travoprost, Investigational

First Posted Date: 2006-02-20

Last Posted Date: 2016-11-18

Lead Sponsor: Alcon Research

Target Recruit Count: 109

Registration Number: NCT00293761

A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

Phase 3

Completed

Conditions: Open-Angle Glaucoma
Ocular Hypertension

Interventions: Drug: Travoprost 0.004%/Timolol 0.5% Ophthalmic Solution
Drug: Latanoprost 0.005% Ophthalmic Solution (XALATAN)
Drug: Timolol 0.5% Ophthalmic Solution
Other: Timolol Vehicle

First Posted Date: 2006-02-20

Last Posted Date: 2012-02-14

Lead Sponsor: Alcon Research

Target Recruit Count: 173

Registration Number: NCT00293800

A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

Phase 3

Completed

Conditions: Open-angle Glaucoma
Ocular Hypertension

Interventions: Drug: Travoprost 0.004% / Timolol 0.5% Ophthalmic Solution
Drug: Latanoprost 0.005% Ophthalmic Solution (XALATAN)
Drug: Timolol Maleate Ophthalmic Solution 0.5%
Other: Timolol Vehicle

First Posted Date: 2006-02-20

Last Posted Date: 2012-02-14

Lead Sponsor: Alcon Research

Target Recruit Count: 156

Registration Number: NCT00293787

Phase III Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-Angle Glaucoma or Ocular Hypertension Patients

Phase 3

Completed

Conditions: Open-angle Glaucoma
Ocular Hypertension

First Posted Date: 2006-02-09

Last Posted Date: 2012-08-17

Lead Sponsor: Alcon Research

Target Recruit Count: 690

Registration Number: NCT00288951

A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

Phase 2

Completed

Conditions: Open-angle Glaucoma
Ocular Hypertension

Interventions: Drug: Timolol Maleate Ophthalmic Gel Forming Solution, 0.5%
Drug: AL-37807 Ophthalmic Suspension, 1.0%
Drug: Latanoprost, 0.005% (Xalatan)
Other: AL-37807 Vehicle

First Posted Date: 2006-02-07

Last Posted Date: 2012-03-05

Lead Sponsor: Alcon Research

Target Recruit Count: 87

Registration Number: NCT00287521

Locations: 🇺🇸
United States Investigative Sites in Texas and Other States, Fort Worth, Texas, United States

Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-angle Glaucoma or Ocular Hypertension Patients

Phase 2

Completed

Conditions: Open-angle Glaucoma
Ocular Hypertension

Interventions: Drug: AL-12182 0.003% Ophthalmic Solution
Other: AL-12182 Ophthalmic Solution Vehicle
Drug: Latanoprost 0.005% Ophthalmic Solution
Drug: AL-12182 0.01% Ophthalmic Solution
Drug: AL-12182 0.03% Ophthalmic Solution

First Posted Date: 2003-10-06

Last Posted Date: 2012-02-14

Lead Sponsor: Alcon Research

Target Recruit Count: 118

Registration Number: NCT00069706

Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-Angle Glaucoma or Ocular Hypertension Patients

Phase 2

Completed

Conditions: Open-Angle Glaucoma
Ocular Hypertension

First Posted Date: 2003-10-06

Last Posted Date: 2008-08-05

Lead Sponsor: Alcon Research

Registration Number: NCT00069719

Locations: 🇺🇸
Alcon Clinical Trial Sites, Multiple Locations Throughout the US Sponsored by Alcon of, Texas, United States

Open-Label Posterior Juxtascleral Injections of Anecortave Acetate 15mg Dose for Long Term Use in Patients With AMD

Phase 3

Terminated

Conditions: Macular Degeneration

Interventions: Drug: Anecortave Acetate (AL-3789) Sterile Suspension, 30 mg/mL

First Posted Date: 2003-08-01

Last Posted Date: 2013-09-16

Lead Sponsor: Alcon Research

Target Recruit Count: 111

Registration Number: NCT00065728

Locations: 🇺🇸
Belgium,France,Germany,Hungary,Italy,Netherlands,Poland,Spain,Sweden,UK, Central Contact Ft. Worth, Texas, United States

Safety and Efficacy Study of BETOPTIC S 0.25% and Timolol Gel-forming Solution 0.25% and 0.5% in Pediatric Patients With Glaucoma or Ocular Hypertension

Phase 3

Completed

Conditions: Glaucoma
Ocular Hypertension

Interventions: Drug: BETOPTIC S (betaxolol HCl)
Drug: Timolol Gel-forming Solution (TGFS)

First Posted Date: 2003-05-30

Last Posted Date: 2016-11-18

Lead Sponsor: Alcon Research

Target Recruit Count: 105

Registration Number: NCT00061542

Locations: 🇺🇸
Alcon Call Center, Fort Worth, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy